Revolutionizing Therapeutic Ultrasound Technology
Pioneering the next generation of therapeutic ultrasound devices,
we are advancing non-invasive solutions to open the blood-brain barrier and transform the future of medical treatment.
BBB Opening
Drug Delivery & Development
for Personalized Treatment
for Diverse Brain Diseases
Product and Technology
Innovative Technology Powering Biotech Advancements
Our non-invasive technology utilizes focused ultrasound to precisely target specific brain regions,
safely opening the blood-brain barrier. This innovation enables the direct delivery of drugs and therapeutic agents to treat a range of brain diseases—eliminating the need for traditional surgical methods.
Real-time Monitoring
Our advanced real-time monitoring technology provides precise insights into the extent and location of BBB opening. This capability enables fine-tuning and optimization of the treatment process, ensuring accuracy and effectiveness.
Personalized Treatment
With real-time monitoring, BBB opening can be tailored to the specific needs of each patient.
By adapting treatment based on individual conditions, we maximize therapeutic outcomes and deliver highly personalized care.
Research & Development Opportunities
Join us in advancing the discovery and development of breakthrough therapies and pharmaceuticals, driving innovation in the treatment of brain diseases.
Revolutionizing Treatment for Brain Diseases
Our technology is designed to treat various brain diseases, including brain tumors and Alzheimer’s. Using Neumous’ ultrasound-based BBB opening technology, we’ve demonstrated exceptional treatment effects in preclinical models for brain tumors and Alzheimer’s. These promising results validate the technology’s effectiveness and clinical potential.
Transforming Drug Development with Value-Up Positioning Technology
Neumous’ value-up positioning technology enables the re-evaluation and repurposing of drugs that were previously limited in clinical trials due to their inability to cross the BBB. By utilizing ultrasound to safely open the BBB, these therapies can now be delivered directly to the brain, unlocking new possibilities for treating brain diseases. This innovative approach breathes new life into drugs that have not yet been applied to neurological conditions.
Highlights
Clinical Medical Device
Officially released in January 2024
Research DeviceOfficially released in December 2024
We are currently in the process of securing approval from the Ministry of Food and Drug Safety.
As part of our global expansion strategy, we have established key partnerships with pharmaceutical companies to enhance treatment efficacy. By leveraging our ultrasound-BBB opening technology, we aim to overcome the challenges posed by the blood-brain barrier and provide effective solutions for brain diseases previously deemed untreatable.
Establishment of Neumous
Ministry of Health and Welfare:
Selected for Brain Drug Delivery Project with $4.2M Research Funding
Over 5 Years
Ministry of SMEs and Startups:
Selected for Deep Tech TIPS Program with $1.3M Research Funding
Over 3 Years
Successfully Developed and Launched the Clinical Medical Device
Ministry of Health and Welfare:
Selected for International Collaboration Project with $1.2M Research Funding
Over 3 Years
Completion of Preclinical Non-Human Primate Study for BBB Opening Performance and Safety Evaluation
Successfully Developed and Launched the Research Device
Designated as Innovative Medical Device by the Ministry of Food and Drug Safety
Awarded the Grand Prize at K-Startup
by the Ministry of SMEs and Startups
Global Expansion Roadmap
At Neumous, our vision knows no boundaries.
As we advance our U.S. expansion, we are collaborating with leading experts from
Harvard Medical School and Georgia Institute of Technology to drive groundbreaking process.
From securing FDA approvals to conducting clinical trials and forging partnerships with
global pharmaceutical leaders, we are redefining the future of brain disease treatment.
Join us on this transformative journey–get in touch today to be part of the innovation.
Media
News & Events
About Us
Meet the Leaders of Neumous
Juyoung (Jay) Park
CEO
Experiences
- Professor, Department of Medical Device, Gachon University
- Principal Investigator, Daegu-Gyeongbuk Medical Innovation Foundation
- Research Fellow, Harvard Medical School
- PostDoctorate, University of Michigan
- Ph.D. Department of Mechanical Engineering, University of Cincinnati
Achievements
- Minister’s Award, Ministry of Health and Welfare
- Presidential Postdoctoral Fellowship Award
- Principal Investigator for national projects (Institute of Brain Science, Innovative doctors and scientists)
- Research Promotion Director, The Korean Society of Brain Neuromodulation Therapy (2023 – Present)
- Founding and Academic Director, Financial Director, The Korean Society for Therapeutic Ultrasound (2015 – Present)
- Korea Food and Drug Administration, Korea Health Industry Development Institute, Medical Device Professional Consultant, Consultant for Korean Agency for Technology and Standard
Partners
